Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Endothelial Antioxidant-1: a Key Mediator of Copper-dependent Wound Healing in vivo.

Scientific reports

Das A, Sudhahar V, Chen GF, Kim HW, Youn SW, Finney L, Vogt S, Yang J, Kweon J, Surenkhuu B, Ushio-Fukai M, Fukai T.
PMID: 27666810
Sci Rep. 2016 Sep 26;6:33783. doi: 10.1038/srep33783.

Copper (Cu), an essential nutrient, promotes wound healing, however, target of Cu action and underlying mechanisms remain elusive. Cu chaperone Antioxidant-1 (Atox1) in the cytosol supplies Cu to the secretory enzymes such as lysyl oxidase (LOX), while Atox1 in...

Cite
Das A, Sudhahar V, Chen GF, et al. Endothelial Antioxidant-1: a Key Mediator of Copper-dependent Wound Healing in vivo. Sci Rep. 2016;6:33783doi: 10.1038/srep33783.
Das, A., Sudhahar, V., Chen, G. F., Kim, H. W., Youn, S. W., Finney, L., Vogt, S., Yang, J., Kweon, J., Surenkhuu, B., Ushio-Fukai, M., & Fukai, T. (2016). Endothelial Antioxidant-1: a Key Mediator of Copper-dependent Wound Healing in vivo. Scientific reports, 633783. https://doi.org/10.1038/srep33783
Das, Archita, et al. "Endothelial Antioxidant-1: a Key Mediator of Copper-dependent Wound Healing in vivo." Scientific reports vol. 6 (2016): 33783. doi: https://doi.org/10.1038/srep33783
Das A, Sudhahar V, Chen GF, Kim HW, Youn SW, Finney L, Vogt S, Yang J, Kweon J, Surenkhuu B, Ushio-Fukai M, Fukai T. Endothelial Antioxidant-1: a Key Mediator of Copper-dependent Wound Healing in vivo. Sci Rep. 2016 Sep 26;6:33783. doi: 10.1038/srep33783. PMID: 27666810; PMCID: PMC5036036.
Copy Download .nbib Format: NLM
Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases.

The ocular surface

Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S.
PMID: 34768002
Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10.

PURPOSE: The current paradigm for therapy of recalcitrant ocular surface diseases (OSD) consists of a sequential, step-up treatment approach. A combinatorial topical therapy (anti-inflammatory/immunosuppressive [steroid] with immunomodulatory [pooled human immune globulin] and tear substitute [serum]) that simultaneously targets several...

Cite
Katz EA, Sunshine S, Mun C, et al. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021;23:1-11doi: 10.1016/j.jtos.2021.11.002.
Katz, E. A., Sunshine, S., Mun, C., Sarwar, M., Surenkhuu, B., Pradeep, A., & Jain, S. (2021). Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. The ocular surface, 231-11. https://doi.org/10.1016/j.jtos.2021.11.002
Katz, Eitan A, et al. "Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases." The ocular surface vol. 23 (2021): 1-11. doi: https://doi.org/10.1016/j.jtos.2021.11.002
Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10. PMID: 34768002.
Copy Download .nbib Format: NLM
Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases.

The ocular surface

Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S.
PMID: 34768002
Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10.

PURPOSE: The current paradigm for therapy of recalcitrant ocular surface diseases (OSD) consists of a sequential, step-up treatment approach. A combinatorial topical therapy (anti-inflammatory/immunosuppressive [steroid] with immunomodulatory [pooled human immune globulin] and tear substitute [serum]) that simultaneously targets several...

Cite
Katz EA, Sunshine S, Mun C, et al. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021;23:1-11doi: 10.1016/j.jtos.2021.11.002.
Katz, E. A., Sunshine, S., Mun, C., Sarwar, M., Surenkhuu, B., Pradeep, A., & Jain, S. (2021). Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. The ocular surface, 231-11. https://doi.org/10.1016/j.jtos.2021.11.002
Katz, Eitan A, et al. "Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases." The ocular surface vol. 23 (2021): 1-11. doi: https://doi.org/10.1016/j.jtos.2021.11.002
Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10. PMID: 34768002.
Copy Download .nbib Format: NLM
MKP-3 suppresses LPS-induced inflammatory responses in HUVECs via inhibition of p38 MAPK/NF-κB pathway.

Animal cells and systems

Unenkhuu B, Kim DB, Kim HS.
PMID: 34408812
Anim Cells Syst (Seoul). 2021 Jul 14;25(4):235-244. doi: 10.1080/19768354.2021.1954551. eCollection 2021.

Endothelial cell dysfunction and inflammatory responses play critical roles in the development of atherosclerosis. Recent data on the processes underlying atherogenesis indicate the substantial role of endotoxins (lipopolysaccharides; LPS) of the intestinal microflora in the initiation and progression of...

Cite
Unenkhuu B, Kim DB, Kim HS. MKP-3 suppresses LPS-induced inflammatory responses in HUVECs via inhibition of p38 MAPK/NF-κB pathway. Anim Cells Syst (Seoul). 2021;25(4):235-244doi: 10.1080/19768354.2021.1954551.
Unenkhuu, B., Kim, D. B., & Kim, H. S. (2021). MKP-3 suppresses LPS-induced inflammatory responses in HUVECs via inhibition of p38 MAPK/NF-κB pathway. Animal cells and systems, 25(4), 235-244. https://doi.org/10.1080/19768354.2021.1954551
Unenkhuu, Banzragchgarav, et al. "MKP-3 suppresses LPS-induced inflammatory responses in HUVECs via inhibition of p38 MAPK/NF-κB pathway." Animal cells and systems vol. 25,4 (2021): 235-244. doi: https://doi.org/10.1080/19768354.2021.1954551
Unenkhuu B, Kim DB, Kim HS. MKP-3 suppresses LPS-induced inflammatory responses in HUVECs via inhibition of p38 MAPK/NF-κB pathway. Anim Cells Syst (Seoul). 2021 Jul 14;25(4):235-244. doi: 10.1080/19768354.2021.1954551. eCollection 2021. PMID: 34408812; PMCID: PMC8366647.
Copy Download .nbib Format: NLM
Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases.

The ocular surface

Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S.
PMID: 34768002
Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10.

PURPOSE: The current paradigm for therapy of recalcitrant ocular surface diseases (OSD) consists of a sequential, step-up treatment approach. A combinatorial topical therapy (anti-inflammatory/immunosuppressive [steroid] with immunomodulatory [pooled human immune globulin] and tear substitute [serum]) that simultaneously targets several...

Cite
Katz EA, Sunshine S, Mun C, et al. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021;23:1-11doi: 10.1016/j.jtos.2021.11.002.
Katz, E. A., Sunshine, S., Mun, C., Sarwar, M., Surenkhuu, B., Pradeep, A., & Jain, S. (2021). Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. The ocular surface, 231-11. https://doi.org/10.1016/j.jtos.2021.11.002
Katz, Eitan A, et al. "Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases." The ocular surface vol. 23 (2021): 1-11. doi: https://doi.org/10.1016/j.jtos.2021.11.002
Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10. PMID: 34768002.
Copy Download .nbib Format: NLM
A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease.

Translational vision science & technology

Mun C, Gulati S, Tibrewal S, Chen YF, An S, Surenkhuu B, Raju I, Buwick M, Ahn A, Kwon JE, Atassi N, Pradeep A, Rondelli D, Jain S.
PMID: 31110911
Transl Vis Sci Technol. 2019 May 02;8(3):10. doi: 10.1167/tvst.8.3.10. eCollection 2019 May.

PURPOSE: To determine whether DNase eye drops have the potential to reduce signs and symptoms of dry eye disease (DED).METHODS: A placebo-controlled, randomized clinical trial was performed to compare the safety and efficacy of DNase eye drops 0.1% four...

Cite
Mun C, Gulati S, Tibrewal S, et al. A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease. Transl Vis Sci Technol. 2019;8(3):10doi: 10.1167/tvst.8.3.10.
Mun, C., Gulati, S., Tibrewal, S., Chen, Y. F., An, S., Surenkhuu, B., Raju, I., Buwick, M., Ahn, A., Kwon, J. E., Atassi, N., Pradeep, A., Rondelli, D., & Jain, S. (2019). A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease. Translational vision science & technology, 8(3), 10. https://doi.org/10.1167/tvst.8.3.10
Mun, Christine, et al. "A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease." Translational vision science & technology vol. 8,3 (2019): 10. doi: https://doi.org/10.1167/tvst.8.3.10
Mun C, Gulati S, Tibrewal S, Chen YF, An S, Surenkhuu B, Raju I, Buwick M, Ahn A, Kwon JE, Atassi N, Pradeep A, Rondelli D, Jain S. A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease. Transl Vis Sci Technol. 2019 May 02;8(3):10. doi: 10.1167/tvst.8.3.10. eCollection 2019 May. PMID: 31110911; PMCID: PMC6504128.
Copy Download .nbib Format: NLM
Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases.

The ocular surface

Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S.
PMID: 34768002
Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10.

PURPOSE: The current paradigm for therapy of recalcitrant ocular surface diseases (OSD) consists of a sequential, step-up treatment approach. A combinatorial topical therapy (anti-inflammatory/immunosuppressive [steroid] with immunomodulatory [pooled human immune globulin] and tear substitute [serum]) that simultaneously targets several...

Cite
Katz EA, Sunshine S, Mun C, et al. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021;23:1-11doi: 10.1016/j.jtos.2021.11.002.
Katz, E. A., Sunshine, S., Mun, C., Sarwar, M., Surenkhuu, B., Pradeep, A., & Jain, S. (2021). Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. The ocular surface, 231-11. https://doi.org/10.1016/j.jtos.2021.11.002
Katz, Eitan A, et al. "Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases." The ocular surface vol. 23 (2021): 1-11. doi: https://doi.org/10.1016/j.jtos.2021.11.002
Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10. PMID: 34768002.
Copy Download .nbib Format: NLM
Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases.

The ocular surface

Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S.
PMID: 34768002
Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10.

PURPOSE: The current paradigm for therapy of recalcitrant ocular surface diseases (OSD) consists of a sequential, step-up treatment approach. A combinatorial topical therapy (anti-inflammatory/immunosuppressive [steroid] with immunomodulatory [pooled human immune globulin] and tear substitute [serum]) that simultaneously targets several...

Cite
Katz EA, Sunshine S, Mun C, et al. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021;23:1-11doi: 10.1016/j.jtos.2021.11.002.
Katz, E. A., Sunshine, S., Mun, C., Sarwar, M., Surenkhuu, B., Pradeep, A., & Jain, S. (2021). Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. The ocular surface, 231-11. https://doi.org/10.1016/j.jtos.2021.11.002
Katz, Eitan A, et al. "Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases." The ocular surface vol. 23 (2021): 1-11. doi: https://doi.org/10.1016/j.jtos.2021.11.002
Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10. PMID: 34768002.
Copy Download .nbib Format: NLM
Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases.

The ocular surface

Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S.
PMID: 34768002
Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10.

PURPOSE: The current paradigm for therapy of recalcitrant ocular surface diseases (OSD) consists of a sequential, step-up treatment approach. A combinatorial topical therapy (anti-inflammatory/immunosuppressive [steroid] with immunomodulatory [pooled human immune globulin] and tear substitute [serum]) that simultaneously targets several...

Cite
Katz EA, Sunshine S, Mun C, et al. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021;23:1-11doi: 10.1016/j.jtos.2021.11.002.
Katz, E. A., Sunshine, S., Mun, C., Sarwar, M., Surenkhuu, B., Pradeep, A., & Jain, S. (2021). Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. The ocular surface, 231-11. https://doi.org/10.1016/j.jtos.2021.11.002
Katz, Eitan A, et al. "Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases." The ocular surface vol. 23 (2021): 1-11. doi: https://doi.org/10.1016/j.jtos.2021.11.002
Katz EA, Sunshine S, Mun C, Sarwar M, Surenkhuu B, Pradeep A, Jain S. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf. 2021 Nov 10;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10. PMID: 34768002.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries